Menu Search
Equities

Myriad Genetics Inc

MYGN:NSQ

Myriad Genetics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)28.29
  • Today's Change-0.18 / -0.63%
  • Shares traded665.04k
  • 1 Year change+62.96%
  • Beta1.9220
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy3
Outperform4
Hold4
Sell3
Strong Sell1

Share price forecast in USD

The 14 analysts offering 12 month price targets for Myriad Genetics, Inc. have a median target of 31.00, with a high estimate of 40.00 and a low estimate of 16.00. The median estimate represents a 9.58% increase from the last price of 28.29.
High41.4%40.00
Med9.6%31.00
Low-43.4%16.00

Earnings history & estimates in USD

On Aug 06, 2024, Myriad Genetics, Inc. reported 2nd quarter 2024 earnings of 0.05 per share. This result exceeded the -0.01 consensus loss of the 13 analysts covering the company and outperformed last year's 2nd quarter results by 0.13.
The next earnings announcement is expected on Nov 04, 2024.
Average growth rate+62.50%
Myriad Genetics, Inc. reported annual 2023 losses of -0.270 per share on Feb 27, 2024.
Average growth rate+48.94%
More ▼

Revenue history & estimates in USD

Myriad Genetics, Inc. had 2nd quarter 2024 revenues of 211.50m. This bettered the 204.95m consensus of the 13 analysts covering the company. This was 16.72% above the prior year's 2nd quarter results.
Average growth rate+3.62%
Myriad Genetics, Inc. had revenues for the full year 2023 of 753.20m. This was 11.03% above the prior year's results.
Average growth rate+8.01%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.